Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men who have sex with men in Aotearoa New Zealand

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-05-12 DOI:10.1016/j.vaccine.2025.127247

Peter Saxton , Brooke Maria Hollingshead , Joe Rich , Simran Saini , Koson Tony Sriamporn , Peter Hanl , Janine Paynter

{"title":"Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men who have sex with men in Aotearoa New Zealand","authors":"Peter Saxton , Brooke Maria Hollingshead , Joe Rich , Simran Saini , Koson Tony Sriamporn , Peter Hanl , Janine Paynter","doi":"10.1016/j.vaccine.2025.127247","DOIUrl":null,"url":null,"abstract":"<div><div>The 2022 multi-country mpox outbreak predominantly affected gay, bisexual, and other men who have sex with men (GBM). As a small country distant from transmission hotspots but vulnerable to imported cases, New Zealand's (NZ) response involved numerous challenges, including low vaccine supplies and lack of regulatory approval, prohibiting vaccine promotion and inhibiting vaccine delivery. We triangulated data sources to estimate mpox vaccine eligibility among GBM. National Immunisation Register data was used to estimate mpox vaccine coverage. Finally, we estimated the probability of a resurgent NZ epidemic using modelling by the US CDC. By April 2024, 3050 individuals had received one mpox vaccine dose and 1065 two doses. National first and second dose coverage among GBM in April 2024 was 12.6 % (range 9.1 %–16.7 %) and 4.4 % (range 2.9 %–5.8 %) respectively. Modelling predicted a > 50 % chance of a future outbreak. With ongoing mpox transmission globally, vaccine coverage among GBM in NZ must urgently increase.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127247"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25005444","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The 2022 multi-country mpox outbreak predominantly affected gay, bisexual, and other men who have sex with men (GBM). As a small country distant from transmission hotspots but vulnerable to imported cases, New Zealand's (NZ) response involved numerous challenges, including low vaccine supplies and lack of regulatory approval, prohibiting vaccine promotion and inhibiting vaccine delivery. We triangulated data sources to estimate mpox vaccine eligibility among GBM. National Immunisation Register data was used to estimate mpox vaccine coverage. Finally, we estimated the probability of a resurgent NZ epidemic using modelling by the US CDC. By April 2024, 3050 individuals had received one mpox vaccine dose and 1065 two doses. National first and second dose coverage among GBM in April 2024 was 12.6 % (range 9.1 %–16.7 %) and 4.4 % (range 2.9 %–5.8 %) respectively. Modelling predicted a > 50 % chance of a future outbreak. With ongoing mpox transmission globally, vaccine coverage among GBM in NZ must urgently increase.

查看原文本刊更多论文

新西兰奥特罗阿男同性恋者、双性恋者和其他男男性行为者的麻疹疫苗接种资格、接种和覆盖率

2022年多国麻疹疫情主要影响同性恋、双性恋和其他男男性行为者（GBM）。作为一个远离传播热点但容易受到输入病例影响的小国，新西兰的应对措施面临许多挑战，包括疫苗供应不足和缺乏监管批准、禁止疫苗推广和抑制疫苗交付。我们对数据来源进行三角分析，以估计GBM中m痘疫苗的适格性。使用国家免疫登记数据估计m痘疫苗覆盖率。最后，我们利用美国疾病控制与预防中心的模型估计了新西兰疫情再次爆发的可能性。到2024年4月，3050人接种了一剂m痘疫苗，1065人接种了两剂。2024年4月全国GBM第一剂和第二剂覆盖率分别为12.6%（9.1% - 16.7%范围）和4.4%（2.9% - 5.8%范围）。模型预测了一个>；未来爆发的几率为50%。随着mpox在全球范围内的持续传播，新西兰GBM的疫苗覆盖率必须紧急增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.